Replies to post #296742 on Amarin Corp Plc (AMRN)

[Dancing in the dark]

Royalty bearing license agreements retain for amarin shareholders the benefits of any future IP developments for icosapent ethyl.

Often wondered how reduce-it phase iii escaped BP partnering. With what is now know about icosapent ethyl and its MOA as an inflammation fighter, I would expect phase iii partnering would be competitive for new pipeline trials.

[dukesking]

This is a tactic used often by BP to combat or discourage skinny label generics from launching and for loss of revenues when exclusivity expires and generics enter naturally. I believe it’s the only viable solution for the US market short of a mutually beneficial agreement with the generics to delay entry till 2026 or later.

[marzan]

This is what Woodcock insisted on us saying she would allow us to have the 'Cardio protective' language on our label, if we agree to go generic. And she did it. I think she approved ANDAs before she moved to lead the Vaccie program. She is a vicious woman and she did it, I bet.